Differential Effects of the G118R, H51Y, and E138K Resistance Substitutions in Different Subtypes of HIV Integrase

Dolutegravir (DTG) is the latest antiretroviral (ARV) approved for the treatment of human immunodeficiency virus (HIV) infection. The G118R substitution, previously identified with MK-2048 and raltegravir, may represent the initial substitution in a dolutegravir resistance pathway. We have found tha...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Virol
Main Authors: Quashie, Peter K., Oliviera, Maureen, Veres, Tamar, Osman, Nathan, Han, Ying-Shan, Hassounah, Said, Lie, Yolanda, Huang, Wei, Mesplède, Thibault, Wainberg, Mark A.
Format: Artigo
Jezik:Inglês
Izdano: American Society for Microbiology 2014
Teme:
Vaccines and Antiviral Agents
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4337543/
https://ncbi.nlm.nih.gov/pubmed/25552724
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.03353-14
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki